Retatrutide · results timeline · research use only
How long does retatrutide take to work? The trial timeline, week by week.
After side effects and dosage, the question people search most about retatrutide (LY3437943) is when it actually starts working — and, like the rest of retatrutide's profile, the answer is measured rather than guessed. The Phase 2 obesity trial (Jastreboff et al., NEJM 2023) tracked body weight over a full 48 weeks and published the least-squares mean change at both 24 and 48 weeks, dose by dose. This page reproduces that trajectory as a research reference: how the 12-week escalation front-loads the early data, what the curve looks like at the 24-week midpoint versus the 48-week endpoint, and the finding that most defines the compound — that weight loss had not levelled off when the study ended. It is a summary of clinical-trial data, not a human-use protocol or medical advice.
The first 12 weeks are escalation
In the trial, no one started at their maintenance dose. Every participant began low and stepped up over a roughly 12-week escalation, then held that dose for the remaining ~36 weeks. So the early timeline is really two things at once: the dose is still climbing while the effect is already building. That is why week-4 and week-8 numbers understate a dose's real potential — the participant simply hasn't reached full dose yet. It also ties to the ~6-day half-life: each step approaches steady-state over about four to five weeks.
See the titration ladder →The 24-week midpoint
By 24 weeks the trial reported clear, dose-dependent separation from placebo. Least-squares mean body-weight change was -7.2% at 1 mg, -12.9% in the combined 4 mg group, -17.3% at 8 mg and -17.5% at 12 mg — versus -1.6% on placebo. In Lilly's own summary that top figure translated to roughly 41 lb of mean reduction at the highest dose. Twenty-four weeks is the point at which the higher arms had already reached the kind of result older single-agonist compounds needed a full year to approach.
How the class compares →The 48-week endpoint
At the 48-week primary endpoint the curve had moved substantially further: -8.7% at 1 mg, -17.1% at the combined 4 mg dose, -22.8% at 8 mg and -24.2% at 12 mg, against -2.1% on placebo. The gap between the 24-week and 48-week numbers is the whole point of the timeline — at the two highest doses, roughly a third of the total change came in the second half of the study, after dose escalation was already complete.
View the compound →It had not plateaued at 48 weeks
The single most-cited feature of the retatrutide data is what the curve was doing when the trial stopped: at the 8 mg and 12 mg doses, body weight was still declining — the trajectory had not flattened by week 48. The investigators explicitly noted weight reduction had not reached a plateau. In practical timeline terms that means the 48-week figure is an endpoint of the study, not a ceiling of the compound, which is exactly why the Phase 3 TRIUMPH program runs longer.
Full research guide →Why 'when' depends on 'which dose'
There is no single retatrutide timeline — there are four, one per dose arm, and they diverge early. The 1 mg arm's entire 48-week result (-8.7%) is smaller than the 12 mg arm's 24-week midpoint (-17.5%). So any honest answer to 'how long does it take to work' is bounded by the target dose and the escalation schedule that gets there. The escalation is a feature, not a delay: a slower ramp is what kept the higher doses tolerable enough to reach in the first place.
Half-life and cadence →Research-use framing
Every figure here describes body-weight outcomes observed in a human clinical trial and is reproduced as a research reference for laboratory and in-vitro modelling — not as a prediction of what any individual would experience, and not as instructions for human use. Retatrutide is an investigational compound with no regulatory approval. Titan supplies it strictly as a research reagent, not for human or animal consumption. Nothing on this page is medical advice.
Research-use policy →The detail, in plain terms
The weight-change timeline, at a glance.
Least-squares mean percentage change in body weight from baseline, drawn from the retatrutide Phase 2 trial (Jastreboff et al., NEJM 2023; n=338, 48 weeks) and reproduced as a research reference. Figures are trial means, not individual predictions.
- Placebo — 24 wk / 48 wk
- -1.6% / -2.1%. The baseline drift the active arms are measured against.
- 1 mg — 24 wk / 48 wk
- -7.2% / -8.7%. The lowest arm; most of its modest total lands by the midpoint.
- 4 mg — 24 wk / 48 wk
- -12.9% / -17.1% (combined 4 mg groups). Clear separation, still climbing after week 24.
- 8 mg — 24 wk / 48 wk
- -17.3% / -22.8% (combined 8 mg groups). ~5 points of additional loss in the second half.
- 12 mg — 24 wk / 48 wk
- -17.5% / -24.2%. The largest arm; roughly a third of its total came after 24 weeks.
- Escalation window
- ~12 weeks of stepped dosing before the maintenance dose; ~36 weeks at dose thereafter.
- Plateau
- None observed at 48 weeks — weight still declining at the two highest doses when the trial ended.
- Half-life
- ~6 days; each dose step approaches steady-state over roughly 4–5 weeks.
Questions researchers ask
Before you order.
- How long does retatrutide take to work in the research?
- In the Phase 2 trial, dose-dependent weight change was already clearly measurable by the 24-week midpoint — least-squares mean reductions of about 7.2% at 1 mg up to 17.5% at 12 mg, versus 1.6% on placebo — and continued to increase through the 48-week endpoint, reaching about 24.2% at 12 mg. Because participants spent the first ~12 weeks escalating the dose, the earliest weeks reflect a still-climbing dose rather than the full effect. These figures come from a human clinical trial and are reproduced as a research reference, not as medical advice.
- What were the retatrutide results at 24 weeks versus 48 weeks?
- At 24 weeks the least-squares mean body-weight change was -7.2% (1 mg), -12.9% (combined 4 mg), -17.3% (8 mg) and -17.5% (12 mg), versus -1.6% placebo. At 48 weeks the same arms reached -8.7%, -17.1%, -22.8% and -24.2%, versus -2.1% placebo. At the two highest doses, roughly a third of the total change occurred in the second half of the study, after dose escalation was complete.
- Did retatrutide's effect plateau?
- No — and this is the most-cited feature of the data. At the 8 mg and 12 mg doses, body weight was still declining at week 48; the investigators noted that weight reduction had not reached a plateau when the trial ended. The 48-week number is therefore the endpoint of that particular study, not a ceiling of the compound, which is part of why the longer Phase 3 TRIUMPH program was designed.
- Why does the timeline depend on the dose?
- There is effectively a separate timeline for each dose arm, and they diverge early. The 1 mg arm's full 48-week result (about -8.7%) is smaller than the 12 mg arm's 24-week midpoint (about -17.5%). Any answer to how long retatrutide takes to work is therefore bounded by the target dose and the roughly 12-week escalation schedule needed to reach it. The gradual ramp is what kept the higher doses tolerable enough to reach.
- Is retatrutide approved for human use?
- No. Retatrutide is an investigational compound with no regulatory approval for human use. Titan Peptide Lab supplies it strictly as a research-use-only reagent for in-vitro laboratory work — not for human or animal consumption, and not for diagnostic, therapeutic, or preventative use. The timeline data on this page is a summary of published clinical research and is not medical or dosing advice.
Related reading